PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “DERMATITIS, ATOPIC”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,297 records · Page 72Linked to original sources

Trends in the prevalence of atopic dermatitis in school children: longitudinal study in Osaka Prefecture, Japan, from 1985 to 1997.

BACKGROUND: The authors have carried out questionnaire surveys of health symptoms in school children (aged 7-12 years) in Osaka Prefecture, Japan. In this study, the geographical distribution of and trends in the prevalence of atopic dermatitis were evaluated. OBJECTIVES: To assess the relationship between the prevalence of atopic dermatitis in children and the environmental factors, and to estimate future changes of the prevalence of atopic dermatitis. METHODS: A total of seven population surveys were carried out at 2-year intervals between 1985 and 1997 in a total of about 4 million primary school children (460 000-740 000 per survey). RESULTS: The lifetime prevalence of atopic dermatitis increased from 15.0% in 1985 to 24.1% in 1993 but levelled off thereafter. According to the school year, the prevalence was higher in lower-year pupils. However, the prevalence stopped rising earlier in lower-year pupils and began to decrease in 1997 in first- to third-year pupils. The prevalence according to areas was significantly correlated negatively with air pollution and positively with the income index. According to the income classes, the prevalence increased until 1993 but levelled off thereafter in all classes, which reduced the differences among the classes. CONCLUSIONS: The increase of the prevalence of atopic dermatitis in school children stopped in 1993 in Osaka Prefecture, Japan. It is conceivable that the prevalence had reached the saturation level.

Air Pollutants↗

[The determination of T-lymphocyte antigenic markers in the serum of patients with atopic dermatitis].

The euglobulin fraction of serum of the patients with atopic dermatitis was studied using monoclonal antibodies OKT3, OKT8 and OKT10 in assay system including secondary 125J labeled anti-mouse IgG antibodies. It was shown that CD3, CD8 and CD38 T-cell marker antigens shed from the T-cell surface could be found in euglobulin fraction of serum patients. The patients with atopic dermatitis successfully treated with immunomodulator vilosen were selected and their serums obtained before and after treatment were investigated. The treatment resulted in the increase of CD8, CD3 determinants and a decrease of antigens determined by OKT10 antibodies (CD38). It is supposed that an increase of CD3 and CD8 determinants is caused by stimulation of T-lymphocyte proliferation and suppressor cell function by vilosen. Since CD38 marker is predominantly on the surface of immature and activated T-cells, which do not occur in circulating blood, it can be supposed that decrease of CD38 in the euglobulin fraction of serum reflects a shedding of these determinants from T-cells of thymus and peripheral lymphoid organs.

Adjuvants, Immunologic↗

[Efficacy of specific immunotherapy in the treatment of children and youngsters suffering from atopic dermatitis Part II. Evaluation of skin reactivity and concentration of serum antigen specific immunoglobulin E directed against selected airborne allergens].

Atopic dermatitis (AD) still remains a difficult clinical problem in terms of effective therapy. The aim of our study was to evaluate efficacy of specific immunotherapy performed with Novo-Helisen Depot allergy vaccines in the group of 36 children and youngsters with atopic dermatitis allergic to house dust mites (24 persons) and grass pollen allergens (12 patients), for the time period of 3 years. Skin reactivity (skin prick tests) and serum concentrations of antigen specific IgE were monitored in the course of treatment. The control group consisted of 20 patients with atopic dermatitis and IgE-mediated airborne allergy who were treated with conventional methods. Specific immunotherapy resulted in negativization of skin prick tests results and decrease of serum antigen specific IgE concentrations. On the contrary in the control group there was no tendency for negativization of skin prick tests and we observed an increase of serum concentration of antigen specific IgE directed against grass pollen allergens. Specific immunotherapy seems to be an effective therapeutic approach in selected cases of atopic dermatitis.

Adolescent↗

Severity scoring of atopic dermatitis: a comparison of three scoring systems.

In studies on atopic dermatitis (AD), different scoring systems are used to evaluate the severity of the disease. The objective of this study was to investigate agreement between observers in the assessment of the overall severity of AD, and interobserver variation in the assessment of severity of AD for each scoring item separately, using the Simple Scoring System (SSS), the Scoring Atopic Dermatitis (SCORAD) index, and the Basic Clinical Scoring System (BCSS), and, furthermore, to investigate agreement between these three scoring systems in the assessment of the overall severity of AD. Eighty-two patients (42 male) with AD, mean age 13.4 years (range 0.2-67.0), were included. Agreement between observers in assessing the overall AD severity scores, and interobserver variation in assessing AD severity of each scoring item separately were determined in 34 of these 82 patients by two physicians scoring the severity of AD by the three scoring systems. To determine agreement between the scoring systems, one physician scored the severity of AD in all patients with the three scoring systems. Agreement between observers and agreement between the three scoring systems was calculated by Cohen's kappa (kappa) and by the measure of agreement according to Bland & Altman. kappa > 0.4 represents fair agreement; kappa > 0.75 excellent agreement. In addition, interobserver variation for each scoring item separately was calculated by the Wilcoxon signed rank test. The mean differences (d) and the limits of agreement (d +/- 2 SD of the differences) between observers by the SSS and the SCORAD were -0.82 +/- 5.58 and -0.28 +/- 7.49, respectively, kappa between observers for the BCSS was 0.90 (95% CI 0.79-1.03). By the SSS, significant interobserver variation was found in assessing the severity of excoriations (P = 0.02) and scales (P = 0.02). By the SCORAD, significant interobserver variation was found in assessing the severity of edema/population (P = 0.04), erythema (P = 0.04), and excoriations (P = 0.01). No significant interobserver variation was found in assessing the extent of AD. The mean difference and the limits of agreement between the SSS and the SCORAD were -4.17 +/- 9.52. kappa between the SSS and the BCSS was 0.21 (95% CI 0.09-0.33), and kappa between the SCORAD and the BCSS was 0.38 (95% CI 0.26-0.51). We found good agreement between observers assessing the overall severity of AD in the lower and higher scoring rates by the SSS and the SCORAD, and excellent agreement by the BCSS. Significant interobserver variation was found on the isolated intensity items scales, excoriations, edema/population, and erythema. We found poor agreement between the three scoring systems in assessing the overall severity of AD, indicating that the SSS, the SCORAD, and the BCSS cannot be used interchangeably to assess the overall severity of AD.

Activities of Daily Living↗

Dose ranging study: cetirizine in the treatment of atopic dermatitis in adults.

One hundred seventy-eight adults with atopic dermatitis were included in this double-blind, parallel, randomized study where the effects of placebo, and cetirizine, 10, 20, and 40 mg administered daily during 4 weeks were measured. Local rescue therapy, which consisted of emollients and 1% hydrocortisone, was permitted and patients in all four groups used it in the same regular way. Severity of atopic dermatitis was measured via the following parameters: pruritus (visual analog scales used by both the investigator and patients), four point scale (absent, slight, moderate and serious) symptom scores for erythema, vesicles, excoriation, and lichenification in 14 body areas and a final visit assessment of the patient's general condition. The patient's quality of sleep was also measured along with standard blood chemistry tests. Adverse events during the study were recorded as well. In total 127 patients were assessed for efficacy. A statistically significant (P < or = .05) improvement was observed in all therapeutic groups for the following parameters: erythema, excoriation, lichenification, total symptom score, area involved, and pruritus. Cetirizine showed a dose-related improvement in the following parameters measured: erythema, lichenification, total symptom score, area involved, final assessment, and pruritus (measured by the patient at each visit). At 40 mg, cetirizine was significantly (P < or = .05) more effective than placebo for these parameters. At 20 mg, this was true only for pruritus (measured by the patient at each visit).(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Topical↗

Localization of interleukin-13 gene-expressing cells in tuberculin reactions and lesional skin from patients with atopic dermatitis.

Interleukin (IL)-13 is a cytokine thought to play an important role in IgE-mediated allergic reactions. The aims of the present study were to localize IL-13 mRNA in positive tuberculin reactions and atopic dermatitis lesions using in situ hybridization and to study the possible influence of atopy on the cytokine gene expression in tuberculin reactions. Punch biopsy specimens were taken from tuberculin reactions in 17 nonatopic and 12 atopic (Phadiatop positive), but otherwise healthy, individuals 72h after injection of purified protein derivative, from chronic lichenified lesions and nonlesional skin in six patients with atopic dermatitis and from normal skin in 12 healthy individuals. IL-13-mRNA-producing cells were located mainly in the dermal-cell infiltrates, both in atopic dermatitis lesions and tuberculin reactions. In the atopic dermatitis lesions, IL-13-mRNA expression was found in close apposition to the epidermis. Higher numbers of IL-13-mRNA-producing cells were observed in the dermal-cell infiltrates of chronic lichenified skin lesions of patients with atopic dermatitis (13.3 cells/mm2, range 0.6-42.4 cells/mm2) than in the tuberculin reactions (1.1 cells/mm2, range 0-3.8 cells/mm2) (P<0.01) despite the larger cell infiltrates in the tuberculin reactions. No significant difference in IL-13 or interferon-gamma gene expression in the tuberculin reactions was seen between atopic and nonatopic individuals.

Adolescent↗

Eosinophils in atopic dermatitis.

The eosinophilic granulocyte is commonly associated with allergic inflammation. Although blood eosinophilia frequently accompanies atopic dermatitis, accumulation of tissue eosinophils is not prominent. Recent studies have elucidated the structure, content, and activities of the eosinophil. In addition, immunofluorescence localization of eosinophil granulate proteins has shown that eosinophils disrupt in tissue depositing toxic granule proteins in several diseases. Here, evidence for eosinophil degranulation in atopic dermatitis is presented and mechanisms whereby eosinophil degranulation may mediate pathophysiologic effects in atopic dermatitis and related conditions are discussed.

Blood Proteins↗

Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis.

Maximal leukocyte histamine release in response to concanavalin A was significantly higher in a group of 16 adult patients with moderate to severe atopic dermatitis when compared to 13 adult nonatopic, normal subjects. In a further four atopic dermatitis patients, histamine release was similar to that in the normal group suggesting the existence of "high-releaser" and "low-releaser" subsets within the atopic dermatitis group. Leukocyte cAMP phosphodiesterase activity was significantly higher in the high-releaser group than in the low-releaser and normal groups. High and low histamine release responses showed strong correlations with high and low phosphodiesterase activities. Pretreatment with the experimental cAMP phosphodiesterase inhibitor Ro-20-1724 in high releasers reduced the histamine release to normal levels. These findings suggest that increased histamine "releasability" in atopic dermatitis is related to abnormalities in cyclic nucleotide regulation. Basophil percentages within the leukocyte preparation and the histamine content per basophil were not significantly different between the atopics and normals. Histamine release did not correlate significantly with serum IgE levels.

3',5'-Cyclic-AMP Phosphodiesterases↗

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.

Tacrolimus ointment is a topical calcineurin inhibitor for the treatment of atopic dermatitis. The primary objective of this open-label study was to assess the long-term safety of tacrolimus ointment. The primary end-point was the incidence of adverse events. Secondary end-points included the Eczema Area and Severity Index and a modified version of this index. A total of 466 children with atopic dermatitis, aged 2-15 years, applied 0.03% or 0.1% tacrolimus ointment twice daily for up to 29.5 months. Skin burning and pruritus were the most common application site events; their prevalence decreased over time. There was no increase in viral infections or other adverse events over time. Laboratory profiles were consistent with those reported in atopic populations. Substantial improvement in all efficacy end-points was observed by week 2 and maintained throughout the study. Long-term treatment with tacrolimus ointment is safe and effective in these patients with atopic dermatitis.

Administration, Topical↗

Improvement of atopic dermatitis and reduction of skin allergic responses by oral intake of konjac ceramide.

Although topical application of ceramide is effective in the treatment of atopic dermatitis, its effect is transient. Thus, the effect of oral intake of ceramide on atopic dermatitis was studied. Two groups of 25 children with moderate atopic dermatitis, who were allergic to house dust mite took either milk sugar (control group) or 1.8 mg/day of konjac ceramide in milk sugar (ceramide group) once a day for 2 weeks. Before and after 2 weeks, skin symptoms were assessed using the SCORAD index, while allergic skin responses to house dust mite were assessed by skin prick test. Moreover, production of allergen-specific IgE and various cytokines by mononuclear cells was measured. After 2 weeks, SCORAD index score, allergic skin responses to house dust mite and house dust mite-specific IgE production were significantly reduced in the ceramide group, but not in the control group. Moreover, house dust mite-induced cytokine production was skewed towards the Th1 type, since production of Th1 cytokine, IFN-gamma, and IL-12, was increased, while production of Th2 cytokine, IL-4, and IL-13, was decreased. In contrast, no change of these parameters was found in control group. Collectively, oral intake of konjac ceramide improved skin symptoms and reduced allergic responses with concomitant skewing of the cytokine pattern towards the Th1 type.

Administration, Oral↗

Oxygen consumption during sleep in atopic dermatitis.

Measurements of oxygen consumption (VO2) were made during sleep in 10 patients with atopic dermatitis. Two groups of healthy children acted as controls. All subjects were studied in bed in an environmental temperature of 24-26 degrees C, and sleep was confirmed during continuous electroencephalographic monitoring. Mean (SD) values of VO2 in sleeping patients who were not scratching ranged from 4.0 (0.4) to 7.4 (0.7), which was not statistically significantly different from control values which ranged from 3.24 (0.3) to 5.56 (0.4). During scratching (while asleep), which occurred in nine out of 10 patients with atopic dermatitis, the mean values of VO2 ranged from 4.5 (0.04) to 10.4 (2.7), and this was significantly higher than the non-scratching patients and the control values. Scratching during sleep in children with atopic dermatitis is associated with increased VO2.

Adolescent↗

Evaluation of minor clinical features of atopic dermatitis.

The diagnostic significance of 19 previously proposed minor features of atopic dermatitis was evaluated. The frequency of these features was studied in 50 patients with typical atopic dermatitis compared to that in 50 control subjects. The ages of all individuals ranged from 3 months to 12 years. Six of the minor features, chelitis, nipple eczema, perifollicular accentuation, white dermographism, recurrent conjunctivitis, and anterior neck folds, were encountered as often in patients as in controls. Two additional features that were of diagnostic significance were diffuse scaling of the scalp and infraauricular fissuring.

Child↗

Atopic dermatitis may be a genetically determined dysmaturation of ectodermal tissue, resulting in disturbed T-lymphocyte maturation. A hypothesis.

Although atopic dermatitis is a skin disorder, it includes immune deviations such as T-cell accumulation and activation in the skin, resulting in chronic, relapsing eczema. The T-lymphocyte activation in the skin is not accompanied by specific allergies in up to two thirds of the patients. It has been shown that T-cell lines and clones can be established from skin biopsies of patients with atopic dermatitis showing cytokine-dependent, but antigen-independent, continuous growth in vitro. This indicates the existence of skin-homing T-lymphocytes with growth requirements different from those of mature T-lymphocytes in the blood. We suggest that atopic dermatitis is a genetically determined change of ectodermal tissue. The thymic epithelium is derived from the ectoderm, and because of that we hypothesize that the maturation of the T-cell immune system of persons who develop atopic dermatitis is disturbed due to a faulty selection of T-lymphocytes in the thymus. "Dys"-matured T-cells leave the thymus as a consequence of faulty selection and continue their growth in the skin. The cells are eventually eradicated by the immune surveillance conducted by the normal part of the patients' immune system and as a consequence of diminished output of faulty selected T-lymphocytes during maturation. Because of the increased proliferation capacity of the aberrant T-cells, a cytokine imbalance occurs and in some patients this leads to the development of type I allergies due to a skewing of the humoral immune system towards IgE production.

Dermatitis, Atopic↗

Two-point discrimination of itch in patients with atopic dermatitis and healthy subjects.

The ability to perceive two pruritic stimuli as separate depending on the distance between them (two-point discrimination of itch) was determined in a single-blind study of 20 patients with atopic dermatitis and 20 healthy subjects. Itch was induced with pairs of histamine injections (0.1 micrograms each) given on the upper arm, either along its axis (longitudinally within a dermatome) or at right angles to it (transversally involving more than one dermatome). The interinjection distances were varied in 3-cm steps until the shortest distance at which the two itching stimuli could be perceived as separate was found. Pairs consisting of one injection of histamine (0.1 micrograms) and one of saline served as controls. The two-point discrimination of itch was significantly better in the atopic dermatitis patients than in the healthy controls, both longitudinally (atopic dermatitis: median 12 cm, range 3-21 cm; healthy controls: 15 cm, range 9-21; p < 0.01) and transversally (atopic dermatitis: median 6 cm, range 3-18; healthy controls: 12 cm, range 6-21; p < 0.001). The two-point discrimination of itch did not correlate with the subject's age, two-point discrimination of touch, or, for the atopic dermatitis patients, with their eczema scores or serum IgE levels. The quality, intensity or spatial summation of itch did not differ significantly between the two groups of subjects.

Adolescent↗

[Risk indicators of reaginic allergy: relations between atopic dermatitis and serum specific IgE of various pneumallergens].

This study was conducted in 1,091 children and adolescents submitted to an allergy check-up for respiratory symptoms. All subjects had a research of IgE for Dermatophagoides pteronyssinus, cat and timothy grass pollen by CAP-System Pharmacia. Three hundred subjects had a personal history of atopic dermatitis. They were compared to the 791 others. No difference was found for age, sex, family history of allergic respiratory disease, breast feeding nor exposure to tobacco smoke. The IgE level was significantly enhanced among subjects with an history of atopic dermatitis, but this difference was due to a higher frequency of sensitisations. In subjects with at least one positive RAST (> 0.35 kIU/l) no significant difference was found (p = 0.41). The highest frequency of sensitisations in case of atopic dermatitis was exclusively related to the simultaneous sensitisation against all the three allergens. Such situation was more frequent when the atopic dermatitis was noted before the age of six months. On the other hand, the sensitisation severity, according to RASTs' classes, was independent of atopic dermatitis history. The author points out the necessity of strong primary preventive measures of pneumallergen environmental avoidance for all infants with atopic dermatitis.

Adolescent↗

The immunological status of children with atopic dermatitis.

We studied 16 children during the quiescent phase of atopic dermatitis with a broad range of in vitro immunological tests. Subnormal levels of IgA were present in 2 children, and subnormal IgG in 1. IgE levels were elevated in 6 children. T cell percentages were significantly but slightly reduced. Normal results were obtained for lymphocyte transformation to 3 mitogens, neutrophil chemotaxis, quantitative iodination and microbicidal activity, and for the serum levels of CH50, C3 and C4. Thus most of the abnormal immunological findings in atopic dermatitis nay be secondary to the disease process itself.

Adolescent↗

Heliotherapy in atopic dermatitis: a prospective study on climatotherapy using the SCORAD index.

The aim of this study was to investigate the suitability and effectiveness of heliotherapy in moderate or severe atopic dermatitis in adults in the Canary Islands. A total of 216 patients participated on 6 different 2- or 3-week heliotherapy trips. Using the Severity Scoring of Atopic Dermatitis Index (SCORAD), the severity of atopic dermatitis was assessed prior to the start of heliotherapy, after 2 weeks and then 3 months after the end of heliotherapy. A quality-of-life questionnaire was later mailed to all participants. The mean SCORAD index was reduced by 70% after 2 weeks of heliotherapy and was still 45% lower 3 months after therapy (P<0.0001). At 3 months, the use of topical steroids was still significantly reduced (P<0.0001), whereas there was no significant (P=0.1166) change in the consumption of emollients. The quality of life of patients was improved and their self-treatment and working capacity was increased. As the longer 3-week period provided no significant additional advantage over a 2-week period, 2 weeks of heliotherapy can be considered optimal. In conclusion, heliotherapy is an effective and valuable therapeutic adjunct, especially in adults with severe atopic dermatitis.

Adolescent↗

Patients with severe atopic dermatitis have activated circulating basophils.

BACKGROUND: The purpose of this study was to define the potential role of the basophil in the pathogenesis of atopic dermatitis by comparing basophil releasibility in patients with food allergy and either mild or severe atopic dermatitis. METHODS: A clinical scoring system was used to differentiate patients into either a low clinical score (LCS) group, 10 patients, or a high clinical score (HCS) group, 14 patients. Basophil histamine release was measured with a radioenzymatic assay, and leukotriene C4 (LTC4) was determined with a radioimmunoassay. Histamine and LTC4 released from basophils spontaneously or after incubation with deuterium oxide, an IgE-dependent histamine-releasing factor, anti-IgE, and C5a were measured. RESULTS: Basophils from the HCS group released more histamine than those from the LCS group when stimulated with deuterium oxide (median percent total release: 85% vs 68%, p < 0.05), with 10 and 100 ng/ml of anti-IgE (58% vs 26% and 62.5% vs 37%, both p < 0.05) and 5 and 50 ng/ml of C5a (50.5% vs 11.5, p < 0.05; 49% vs 11%, p < 0.01, respectively). The spontaneous release of LTC4 from basophils was greater in the HCS group (median release: 34 vs 3.5 pg/0.1 ml, p < 0.05). Basophils stimulated with deuterium oxide, with 100 ng/ml anti-IgE, and 50 ng/ml C5a released more LTC4 in the HCS group (111.5 vs 39 pg/0.1 ml, p < 0.05; 64.5 vs 10 pg/0.1 ml, p < 0.01; 80 vs 1 pg/0.1 ml, p < 0.05, respectively). CONCLUSIONS: These data indicate that patients with more severe atopic dermatitis have "activated" circulating basophils in vivo and increased basophil releasibility, in particular in response to C5a. These studies may serve as markers for more severe atopic dermatitis.

Adolescent↗